These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 808605)

  • 1. Emetic activity of N-substituted norapomorphines.
    Atkinson ER; Bullock FJ; Granchelli FE; Archer S; Rosenberg FJ; Teiger DG; Nachod FC
    J Med Chem; 1975 Oct; 18(10):1000-3. PubMed ID: 808605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Derivatives of apomorphine and of other N-substituted norapomorphines.
    Atkinson ER; Battista SP; Ary IE; Richardson DG; Harris LS; Dewey WL
    J Pharm Sci; 1976 Nov; 65(11):1682-5. PubMed ID: 994002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aporphines. 8. Total synthesis and pharmacological evaluation of (plus or minus)-apomorphine, (plus or minus)-apocodeine, (plus or minus)-N-n-propylnorapomorphine, and (plus or minus)-N-n-propylnorapocodeine.
    Neumeyer JL; Neustadt BR; Oh KH; Weinhardt KK; Boyce CB; Rosenberg FJ; Teiger DG
    J Med Chem; 1973 Nov; 16(11):1223-8. PubMed ID: 4201182
    [No Abstract]   [Full Text] [Related]  

  • 4. Synthesis and biological activity of (6aS)-10,11-dihydroxyaporphine, the optical antipode of apomorphine.
    Saari WS; King SW
    J Med Chem; 1973 Feb; 16(2):171-2. PubMed ID: 4683115
    [No Abstract]   [Full Text] [Related]  

  • 5. Centrally acting emetics. 10. Rigid dopamine congeners derived from octahydrobenzo[f]quinoline.
    Cannon JG; Hatheway GJ
    J Med Chem; 1976 Aug; 19(8):987-93. PubMed ID: 184283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain.
    Gao YG; Ram VJ; Campbell A; Kula NS; Baldessarini RJ; Neumeyer JL
    J Med Chem; 1990 Jan; 33(1):39-44. PubMed ID: 2136919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centrally acting emetics. 5. Preparation and pharmacology of 10-hydroxy-11 methoxyaporphine (isoapocodeine). In vitro enzymatic methylation of apomorphine.
    Cannon JG; Smith RV; Modiri A; Sood SP; Borgman RJ; Aleem MA; Long JP
    J Med Chem; 1972 Mar; 15(3):273-6. PubMed ID: 5059211
    [No Abstract]   [Full Text] [Related]  

  • 8. Centrally acting emetics. II. Norapomorphine and derivatives.
    Koch MV; Cannon JG; Burkman AM
    J Med Chem; 1968 Sep; 11(5):977-81. PubMed ID: 5697109
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopaminergic effects of non-hydroxylated rigid analogs of apomorphine.
    Rusterholz DB; Long JP; Flynn JR; Cannon JG; Lee T; Pease JP; Clemens JA; Wong DT; Bymaster FP
    Eur J Pharmacol; 1979 Apr; 55(1):73-82. PubMed ID: 571341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emetic effect of triazolopyrimidine, a pyrimidine compound, in dogs.
    Akahori F; Ichimura T; Masaoka T; Arai S
    Vet Hum Toxicol; 1985 Oct; 27(5):381-5. PubMed ID: 4060556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of apomorphine-induced behaviors by derivatives of 2-amino-1, 2, 3, 4-tetrahydronaphthalene.
    Rusterholz DB; Long JP; Flynn JR; Glyn JR; Barfknecht CF; Lind RW; Johnson AK
    Arch Int Pharmacodyn Ther; 1978 Apr; 232(2):246-60. PubMed ID: 567044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Centrally acting emetics. 8. Conformational aspects of certain dihydrophenanthrene congeners of apomorphine.
    Cannon JG; Smith RV; Aleem MA; Long JP
    J Med Chem; 1975 Jan; 18(1):108-10. PubMed ID: 1109566
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of the sympathetic nervous system by 5,6-dihydroxy-2-dimethylamino tetralin (M-7), apomorphine and dopamine.
    Long JP; Heintz S; Cannon JG; Kim J
    J Pharmacol Exp Ther; 1975 Feb; 192(2):336-42. PubMed ID: 1117421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of emetic and antiemetic activity.
    Burkman AM
    J Pharmacol Methods; 1982 Nov; 8(3):165-71. PubMed ID: 7154672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Centrally acting emetics. 6. Derivatives of -naphthylamine and 2-indanamine.
    Cannon JG; Kim JC; Aleem MA
    J Med Chem; 1972 Apr; 15(4):348-50. PubMed ID: 5019548
    [No Abstract]   [Full Text] [Related]  

  • 16. Enkephalin receptors in the emetic chemoreceptor trigger zone of the dog.
    Bhargava KP; Dixit KS; Gupta YK
    Br J Pharmacol; 1981 Mar; 72(3):471-5. PubMed ID: 6266566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophysiologic and hemodynamic effects of apomorphine in dogs.
    Nakayama H; Nakayama T; Carnes CA; Strauch SM; Hamlin RL
    Toxicol Appl Pharmacol; 2001 Dec; 177(2):157-61. PubMed ID: 11740914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of subcutaneous versus intravenous administration of apomorphine for induction of emesis in dogs.
    Fischer C; Drobatz KJ; Thawley VJ
    J Am Vet Med Assoc; 2021 Aug; 259(3):283-287. PubMed ID: 34242075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of brain dopaminergic mechanisms in rodent aggressive behavior: influence of (+/-)N-n-propyl-norapomorphine on three experimental models.
    Baggio G; Ferrari F
    Psychopharmacology (Berl); 1980; 70(1):63-8. PubMed ID: 6775337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emetic and antiemetic effects of opioids in the dog.
    Blancquaert JP; Lefebvre RA; Willems JL
    Eur J Pharmacol; 1986 Sep; 128(3):143-50. PubMed ID: 3024991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.